Back to Acceleration Radar
ARWRArrowhead Pharmaceuticals Inc
Health Care · Biotechnology: Pharmaceutical Preparations · Large
$58.02−0.58%
As of 23 Oct 2026Mkt cap $12.1B
Stage 13
AVOID
Fundamentals
20.2/75
Technical
4.7/15
Independent
24.9/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −12.2%
- 3M
- −32.2%
- 6M
- −21.5%
- 1Y
- +54.2%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 19.3%
- Operating margin
- -85.2%
- FCF margin
- 18.9%
- Current ratio
- 4.9x
Growth
- Revenue growth
- +23258.2%Latest FY YoY
- Revenue CAGR
- +56.5%
- EPS CAGR
- —
- FCF CAGR
- +1.5%
Capital
- Share-count trend
- +11.9%3Y annualised
- Net cash
- $115M-0.6x OCF
Annual trend
- CAGR 2021–2025
- +56.5%
- Latest · 2025
- $1B
- YoY
- +23258.2%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-24
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded